Lupin receives US FDA approval for Mirabegron Extended-Release tablets

Mirabegron Extended-Release Tablets, 25 mg and 50 mg, had estimated annual sales of US $2.4 billion in US

Lupin launches Sildenafil for Oral Suspension in US

Sildenafil for Oral Suspension (RLD Revatio) had estimated annual sales of US $64 million in the US

Novartis unveils new focused strategy

Transformation to pure-play Innovative Medicines company nears completion

Aptar Pharma collaborates with Fluidda

The companies will leverage their respective proprietary technology platforms

Lupin receives approval from US FDA for Diclofenac Sodium Topical Solution USP

Diclofenac Sodium Topical Solution USP, 2% w/w (RLD Pennsaid) had estimated annual sales of US $484 million in the US

U.S. District Court rules in favor of Merck in Sitagliptin Phosphate patent lawsuit

Sitagliptin is an active ingredient in JANUVIA, JANUMET and JANUMET XR

Shilpa Medicare receives tentative approval for Tenofovir Alafenamide Tablets

The ANDA was filed as 'First to File' submission on NCE-1 date.

Bayer chronic kidney disease medication Kerendia can gain quick market penetration in India, says GlobalData

Affordable Sitagliptin combinations for diabetics to be sold at Janaushadhi Kendras

Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Zydus receives final approval from USFDA for Cariprazine Capsules

Cariprazine is an atypical antipsychotic indicated for the treatment of schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder